Strengthening public health across Lebanon with EIB Global

On March 6, 2025, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus and European Investment Bank (EIB Global) Vice-President Thomas Östros convened at the high-profile EIB Group Forum held in Luxembourg to formalize a critical partnership. The leaders signed a landmark agreement securing a €10 million grant aimed at bolstering public health infrastructure and delivering life-saving medical care across Lebanon. This strategic financial injection arrives at a vital juncture for the Mediterranean nation, which has faced cascading economic turmoil, geopolitical instability, and severe strain on its healthcare delivery systems over recent years.

The joint initiative focuses on two critical pillars: the full re-establishment and modernization of Lebanon’s long-dormant Central Public Health Laboratory, and the direct procurement and distribution of essential medications for more than 50,000 vulnerable individuals suffering from chronic, non-communicable diseases (NCDs) such as diabetes, cardiovascular disorders, and various forms of cancer. By addressing both institutional diagnostic capabilities and direct patient needs, the EIB Global and WHO partnership seeks to avert further deterioration of health indicators in a population already overburdened by compounding crises.

The Genesis of the Crisis: Background Context on Lebanon’s Healthcare Collapse

To understand the magnitude of the €10 million grant, it is necessary to examine the severe degradation of Lebanon’s health sector. For decades, Lebanon was often regarded as the medical hub of the Middle East, boasting a robust private healthcare infrastructure, advanced tertiary hospitals, and a skilled cadre of medical professionals trained to international standards. However, the nation’s systemic collapse—sparked in late 2019 by a severe financial and banking crisis, exacerbated by the catastrophic August 2020 Beirut Port explosion, and further compounded by regional conflicts—dismantled much of this architecture.

The devaluation of the Lebanese pound by more than 90% obliterated the purchasing power of the state and its citizens. Consequently, the Lebanese Ministry of Public Health struggled to subsidize basic pharmaceuticals, leading to chronic nationwide shortages of essential medicines. Hospitals faced severe electricity blackouts due to fuel shortages, relying heavily on failing generator systems and humanitarian fuel allocations.

Furthermore, the brain drain of medical personnel has been staggering. Thousands of doctors, nurses, and laboratory technicians emigrated in search of stable livelihoods abroad, leaving public hospitals and clinics severely understaffed. Within this fragile ecosystem, institutional oversight mechanisms—most notably the Central Public Health Laboratory—suffered immense structural and operational setbacks. Without a functioning national reference laboratory, Lebanon’s capacity to conduct epidemiological surveillance, monitor food and water safety, verify pharmaceutical quality, and detect emerging infectious disease outbreaks was drastically compromised.

Chronology of Events Leading to the March 2025 Agreement

The path toward the March 6, 2025 agreement reflects a sustained international effort to stabilize Lebanon’s public sector through targeted humanitarian and developmental interventions.

In the immediate aftermath of the 2020 Beirut Port explosion, international health organizations pivoted from long-term developmental planning to emergency relief, channeling millions of dollars into trauma care and emergency pharmaceutical supplies. Despite these infusions, chronic disease management remained severely underfunded, as emergency funds were necessarily prioritized for acute care and pandemic response during the COVID-19 years.

Throughout 2023 and 2024, the WHO, alongside regional partners and European institutions, conducted comprehensive assessments of Lebanon’s health infrastructure. These evaluations consistently highlighted the critical vulnerability of patients with non-communicable diseases. Data revealed that cardiovascular diseases, cancer, and diabetes accounted for the vast majority of morbidity and mortality in Lebanon, yet access to regular treatment regimens had become an unaffordable luxury for a large portion of the populace.

Simultaneously, planning for the rehabilitation of the Central Public Health Laboratory gained momentum. Stakeholders recognized that relying on decentralized or makeshift testing facilities posed a significant biosecurity and public health risk. Discussions between EIB Global and the WHO intensified in late 2024, culminating in the finalization of the €10 million grant proposal. The signing ceremony at the EIB Group Forum in Luxembourg on March 6, 2025, marked the official transition from planning to execution, setting a definitive timeline for infrastructure reconstruction and medical supply chains to roll out across Lebanese governorates.

Supporting Data: The Human and Institutional Toll

The urgency of the EIB Global and WHO intervention is underscored by sobering statistical data regarding health vulnerabilities in Lebanon. According to recent WHO health sector reports, non-communicable diseases account for approximately 90% of all deaths in the country. Before the economic collapse, Lebanon’s healthcare system heavily subsidized chronic disease treatments, ensuring high compliance and manageable health outcomes for patients.

However, following the lifting of broad medication subsidies by the central bank, the cost of insulin, chemotherapy drugs, and antihypertensive medications skyrocketed beyond the reach of average families. Surveys conducted by international humanitarian agencies indicated that over 60% of households with a chronic disease patient had to cut back on or completely stop purchasing necessary medications due to prohibitive costs.

The targeted demographic of the new initiative—the 50,000 individuals suffering from diabetes, cardiovascular issues, and cancer—represents a fraction of the total need, but targets the most acute cases requiring continuous pharmacological intervention. Disruptions in the treatment of these conditions frequently lead to catastrophic health outcomes, including strokes, heart attacks, advanced cancer progression, and acute diabetic complications, which in turn place an unsustainable burden on emergency hospital departments.

On the institutional side, the Central Public Health Laboratory serves as the backbone of national health security. Prior to its degradation, the laboratory processed tens of thousands of samples annually, acting as the ultimate authority for disease control, antimicrobial resistance tracking, and environmental health monitoring. The re-establishment of this facility under modern international standards will restore Lebanon’s compliance with global health security frameworks, enabling rapid identification of pathogens and ensuring consumer safety across food and pharmaceutical supply chains.

Official Responses and Perspectives from Leadership

Speaking at the EIB Group Forum in Luxembourg, leaders from both institutions emphasized the strategic and humanitarian importance of the agreement.

Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, underscored the interconnected nature of health, stability, and human dignity. He noted that the collapse of a nation’s public health laboratory system leaves it blind to emerging threats, while the denial of essential medicines to chronic disease patients constitutes a quiet humanitarian crisis. Dr. Tedros praised the European Investment Bank for its steadfast commitment to global health equity, emphasizing that the €10 million grant is not merely financial assistance, but an investment in resilience. He reiterated the WHO’s operational commitment on the ground in Lebanon, assuring stakeholders that the organization would oversee the transparent implementation of the project to ensure that supplies reach those most in need without administrative bottlenecks.

Representing the financial partner, Thomas Östros, Vice-President of EIB Global, highlighted the bank’s evolving role in supporting sustainable development and crisis recovery beyond European borders. EIB Global, the specialized arm of the European Investment Bank Group dedicated to outside-EU operations, has increasingly focused on social infrastructure projects that foster long-term stability. Östros remarked that economic recovery is impossible without a healthy workforce and secure communities. He stressed that by partnering with the WHO, EIB Global leverages the technical expertise of the United Nations agency to ensure that European taxpayer funds are deployed with maximum efficiency and high-impact socioeconomic returns.

Lebanese health authorities and civil society organizations have also welcomed the announcement. While local officials acknowledge that €10 million cannot single-handedly solve every structural deficit in the national healthcare ecosystem, they view the rebuilding of the central laboratory and the targeted support for chronic disease patients as vital lifelines that prevent total systemic failure.

Fact-Based Analysis of Implications and Broader Impact

The implications of the €10 million EIB Global-WHO initiative extend across several dimensions: public health security, economic relief, and international development strategy.

First, from a public health security perspective, the reconstruction of the Central Public Health Laboratory re-establishes a crucial line of defense. In an interconnected world, a blind spot in national epidemiological surveillance poses risks not only to Lebanon but to the broader Eastern Mediterranean region and international travel networks. By equipping the laboratory with modern diagnostic technologies and retraining local personnel to international standards, the project restores Lebanon’s ability to conduct genomic sequencing, monitor viral mutations, and enforce stringent quality control on imported foodstuffs and medical products.

Second, the targeted medical provision for 50,000 chronic disease patients carries profound economic and social implications. When individuals with conditions like diabetes or cardiovascular disease are forced to forgo medication, they frequently suffer debilitating acute medical events that require expensive hospitalization, intensive care unit admissions, or surgical interventions. By providing a reliable, sustained stream of pharmaceuticals for these patients, the initiative prevents medical impoverishment—a phenomenon where families exhaust their remaining savings on healthcare—and reduces the load on public hospitals, allowing those facilities to redirect scarce resources toward emergency and trauma services.

Third, the partnership model itself serves as a blueprint for future developmental interventions in fragile and conflict-affected states (FCAS). Traditional funding models often struggle with institutional corruption, bureaucratic inertia, or lack of local technical capacity. By pairing the financial muscle and project governance of the European Investment Bank with the on-the-ground operational footprint and technical authority of the World Health Organization, the initiative establishes a secure implementation pipeline. This mechanism ensures rigorous monitoring, transparent procurement processes, and direct accountability to donors and beneficiaries alike.

Conclusion and Outlook

As implementation gets underway following the March 2025 signing ceremony, the international community will closely monitor the progress of the Central Public Health Laboratory’s reconstruction and the distribution of medications to Lebanon’s vulnerable chronic disease patients. While deep structural challenges remain within Lebanon’s political and economic spheres, this €10 million grant represents a tangible, evidence-based intervention that addresses both immediate human suffering and long-term institutional resilience. Through the concerted efforts of the World Health Organization and EIB Global, a vital foundation is being laid to help Lebanon navigate its protracted crisis and safeguard the health and well-being of its population for years to come.